Literature DB >> 10657449

An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma.

J S Chana1, R Grover, G D Wilson, D A Hudson, M Forders, R Sanders, A O Grobbelaar.   

Abstract

Acral lentiginous melanoma is a particularly aggressive melanocytic lesion but, due to its comparative rarity, biological investigations into the behaviour of this subtype of melanoma are lacking. The activity of the recently described p16 tumour suppressor gene, thought to be the 'familial melanoma gene', was studied in 24 patients with subungual melanoma and 44 patients with plantar melanoma. Lower levels of p16 oncoprotein were demonstrated than that found in other histogenetic types of melanoma. Stratification of patients of all disease stages revealed a poorer survival in patients with low p16 expression (log rank test, chi(2)= 3.9, P = 0. 05). These data suggest that p16 inactivation may play an important role in the development and progression of acral lentiginous melanomas. However, the level of p16 expression was not prognostic since survival analysis on stratification of stage I patients according to p16 level did not reach statistical significance for both survival and disease free interval. Copyright 2000 The British Association of Plastic Surgeons.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10657449     DOI: 10.1054/bjps.1999.3232

Source DB:  PubMed          Journal:  Br J Plast Surg        ISSN: 0007-1226


  2 in total

1.  P16 protein expression in primary cutaneous melanoma with positive and negative lymph node biopsies: Particular aspects of a study performed at the Hospital de Clinicas de Porto Alegre, Brazil.

Authors:  Jac Fauri; F Ricardi; Es Diehl; A Cartell; R Furian; L Bakos; Mi Edelweiss
Journal:  Can J Plast Surg       Date:  2011

2.  A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma.

Authors:  Arnaud Uguen; Matthieu Talagas; Sebastian Costa; Sandrine Duigou; Stéphanie Bouvier; Marc De Braekeleer; Pascale Marcorelles
Journal:  Diagn Pathol       Date:  2015-10-26       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.